Literature DB >> 30844308

Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.

Jane M Simoni1,2,3, Kristin Beima-Sofie2, Zahra H Mohamed2, Joan Christodoulou4, Kenneth Tapia2, Susan M Graham2,5,6, Rodney Ho7,8, Ann C Collier6.   

Abstract

To better understand acceptability of long-acting injectable antiretroviral treatment (LAI-ART) regimens for HIV management, we conducted seven semi-structured focus group discussions with experienced HIV care providers and persons living with HIV (PLWH) and five individual interviews with parents of children living with HIV in the western United States. Although providers were wary about a potential negative impact on consistent engagement in care, they predicted that patients, especially those with adherence challenges, would be enthusiastic about LAI options. Many PLWH, especially young adults, welcomed the option of an LAI-ART regimen; however, others feared injections and expressed concerns about possible side effects, dosing more frequent than every 2 weeks, additional costs, and lower efficacy. Parents' interest varied according to their child's age and sensitivity to injections. In summary, potential users considered LAI-ART generally acceptable yet voiced possible concerns as well, especially if their current pill-based regimen was effective in achieving viral suppression.

Entities:  

Keywords:  HIV/AIDS; acceptability; long-acting injectable ART; qualitative

Mesh:

Substances:

Year:  2019        PMID: 30844308      PMCID: PMC6442271          DOI: 10.1089/apc.2018.0198

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.944


  20 in total

1.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

Review 2.  The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?

Authors:  Thomas P Giordano; Maria E Suarez-Almazor; Richard M Grimes
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 3.  Antiretroviral implants for treatment and prevention of HIV infection.

Authors:  Charles Flexner
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

Review 4.  Implementation challenges for long-acting antivirals as treatment.

Authors:  Diane Havlir; Monica Gandhi
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

5.  Long-acting HIV drugs advanced to overcome adherence challenge.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

6.  Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.

Authors:  Holly M Burke; Mario Chen; Mercy Buluzi; Rachael Fuchs; Silver Wevill; Lalitha Venkatasubramanian; Leila Dal Santo; Bagrey Ngwira
Journal:  Lancet Glob Health       Date:  2018-03-08       Impact factor: 26.763

7.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

8.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321

Review 9.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

Review 10.  Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment-Clinical Points of View and Practical Considerations.

Authors:  Simona A Iacob; Diana G Iacob; Gheorghita Jugulete
Journal:  Front Pharmacol       Date:  2017-11-23       Impact factor: 5.810

View more
  18 in total

1.  Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.

Authors:  Karine Dubé; Danielle M Campbell; Kelly E Perry; John T Kanazawa; Parya Saberi; John A Sauceda; Tonia Poteat; David Evans
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-14       Impact factor: 2.205

2.  The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.

Authors:  Karine Dubé; Shadi Eskaf; David Evans; John Sauceda; Parya Saberi; Brandon Brown; Dawn Averitt; Krista Martel; Maria Meija; Danielle Campbell; Liz Barr; John Kanazawa; Kelly Perry; Hursch Patel; Stuart Luter; Tonia Poteat; Judith D Auerbach; David A Wohl
Journal:  AIDS Res Hum Retroviruses       Date:  2019-12-04       Impact factor: 2.205

Review 3.  The arc of HIV epidemics in sub-Saharan Africa: new challenges with concentrating epidemics in the era of 90-90-90.

Authors:  Katrina F Ortblad; Jared M Baeten; Peter Cherutich; Joyce Njeri Wamicwe; Judith N Wasserheit
Journal:  Curr Opin HIV AIDS       Date:  2019-09       Impact factor: 4.283

4.  Equity in access to long-acting injectables in the USA.

Authors:  J Carlo Hojilla; Monica Gandhi; Derek D Satre; Mallory O Johnson; Parya Saberi
Journal:  Lancet HIV       Date:  2022-02-04       Impact factor: 12.767

5.  Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.

Authors:  Morgan M Philbin; Sadie Bergen; Carrigan Parish; Deanna Kerrigan; Elizabeth N Kinnard; Sarah Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Michael Vaughn; José I Gutierrez; Margaret A Fischl; Maria Alcaide; Lisa R Metsch
Journal:  AIDS Behav       Date:  2021-10-14

6.  A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.

Authors:  Morgan M Philbin; Carrigan Parish; Sadie Bergen; Deanna Kerrigan; Elizabeth N Kinnard; Sarah E Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Margaret Fischl; Maria L Alcaide; Lisa R Metsch
Journal:  AIDS Patient Care STDS       Date:  2021-01       Impact factor: 5.078

7.  "Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya.

Authors:  Jane M Simoni; Kristin Beima-Sofie; George Wanje; Zahra H Mohamed; Kenneth Tapia; R Scott McClelland; Rodney J Y Ho; Ann C Collier; Susan M Graham
Journal:  J Int Assoc Provid AIDS Care       Date:  2021 Jan-Dec

8.  A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.

Authors:  Jane M Simoni; Kenneth Tapia; Sung-Jae Lee; Susan M Graham; Kristin Beima-Sofie; Zahra H Mohamed; Joan Christodoulou; Rodney Ho; Ann C Collier
Journal:  AIDS Behav       Date:  2020-04

9.  Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.

Authors:  Morgan M Philbin; Carrigan L Parish; Elizabeth N Kinnard; Sarah E Reed; Deanna Kerrigan; Maria L Alcaide; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Margaret Fischl; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2020-07-01       Impact factor: 3.771

Review 10.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.